NCT03456700View on ClinicalTrials.gov

Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

PHASE2TerminatedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

March 30, 2018

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions

Ovarian Serous TumorRecurrent Ovarian Carcinoma

Interventions

DRUG

Auranofin

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Sirolimus

Given PO

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER